AI-Enhanced MRI
Computational reconstruction intended to extract substantially more diagnostic information from constrained MRI systems.
We invent medical technologies for problems that look impossibly hard — from intelligent imaging and diagnostics to surgical AI, precision medicine and biomedical devices.
The AI-Enhanced MRI concept combines scanner-compatible acquisition, computational reconstruction, artifact correction and clinical AI into a new layer between the scanner and the radiologist.
A proposed table-side hardware system designed to accept low-quality or constrained MRI outputs, process them through an AI reconstruction pipeline, and deliver an enhanced digital image for radiologist review.
Scanner-compatible acquisition and data intake.
Low-quality or constrained MRI enters the processing unit.
AI reconstruction, denoising, artifact correction and super-resolution where validated.
Enhanced images are surfaced in a radiologist-facing workflow.
Quality metrics, auditability and clinician feedback inform the R&D loop.
Metisova Medical is designed as a medical invention company — combining medicine, AI, engineering, computation and biology rather than building a single-product identity.
Computational reconstruction intended to extract substantially more diagnostic information from constrained MRI systems.
Perception, anatomy recognition, workflow intelligence, navigation and decision support for future operating rooms.
Multimodal, rapid and computational diagnostic technologies designed around sensitivity, specificity, speed and access.
Patient-specific models combining imaging, clinical information, laboratory data and — where appropriate — genomics.
Physical systems for diagnostic, monitoring, acquisition and intelligent clinical workflows.
Robotic assistance, rehabilitation, teleoperation and future autonomous or semi-autonomous medical functions.
Connected clinical data, decision support, workflow systems, security and interoperable healthcare infrastructure.
Broader Metisova life-sciences R&D, including an ambitious ultra-low-cost genome sequencing research target.
The portfolio is intentionally a pipeline. Concepts become prototypes, prototypes become validated technologies, and validated technologies can become products.
Find an important clinical problem.
Understand the science and clinical context.
Build the missing technology.
Bench, technical and clinical evidence.
Regulatory pathway, manufacturing and deployment.
Metisova Medical is positioned closer to a medical-technology and scientific invention company than a conventional healthcare provider. The opportunity is a portfolio of deep-tech programs connected by shared AI, engineering, data and research capabilities.
Research partner. Hospital. Radiology group. Engineer. Investor. Scientist. Strategic partner.